RHRebecca Halligan

Rebecca Halligan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca Halligan has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Helen Mundy

    Department of Paediatric Inherited Metabolic Diseases, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK

    3 shared publications
  • Charles Turner

    WellChild Laboratory, Evelina London Children’s Hospital, London, UK

    2 shared publications
  • Helen R. Mundy

    Department of Paediatric Inherited Metabolic Diseases Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust London UK

    2 shared publications
  • Joanna Gribben

    Department of Paediatric Inherited Metabolic Diseases Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust London UK

    2 shared publications
  • Katherine Lewis

    Evelina London Children's Hospital

    2 shared publications
  • Oliver Heath

    Department of Metabolic Medicine The Royal Children's Hospital Melbourne Australia

    2 shared publications

Latest Publications

  • Hepatic Glycogen Storage Disease Type IX : Long‐Term Outcomes in the UK From 89 Patients

    by Rebecca K. Halligan, Michael T. Sanders, Arthavan Selvanathan, Nirubhan Veeraghavan, Isaac Bernhardt, Joanna Gribben, Radha Ramachandran, Fiona J. White, Bernd C. Schwahn, Karolina M. Stepien, et al.

    Hepatic glycogen storage disease type IX (GSD IX) is due to a deficiency of phosphorylase kinase and is one of the most common types of GSD. We conducted a retrospective, observational cohort study on individuals with GSD IX from across the United Kingdom. We describe the natural history and long‐term outcomes for 89 individuals with GSD IX with a median age of 16.4 years (range 4 months to 73 years). This included 60 patients with IXα2, 12 with IXβ and 13 with IXγ2. We report 49 novel alleles in PHKA2, PHKB and PHKG2 . The median age at initial presentation was 2.5 years, with 82% ( n = 68) presenting with hepatomegaly and 46% ( n = 38) presenting with ketotic hypoglycaemia. Steatosis was reported in 71% ( n = 12) who had a liver biopsy. The mean Z‐score for height at initial presentation was −1.21, and this significantly improved over childhood. A spectrum of severity was seen in all subtypes, with some requiring more intensive dietary management after initial presentation and others requiring no formal dietary treatment at all. No patients developed adenomas or hepatocellular carcinomas, and 75% ( n = 33) of adults were on no dietary therapy. Individuals with IXγ2 had a more severe disease course and had significantly worse biochemistry at initial presentation compared to other subtypes. They were diagnosed at a younger age and required more intensive dietary management across the lifespan. We believe that GSD IXγ2 is an ideal target for novel therapies. We recommend regular monitoring and multidisciplinary input in all patients with GSD IX and encourage more formal assessment of protein intake with each review.

  • Open Access

    COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy

    by Micol Falabella, Sandra Lopez Calcerrada, Jana Aref, Jiaze Gao, William L. Macken, Chiara Pizzamiglio, Renata Kabiljo, Anna Lucia Francavilla, Pauline Gaignard, Antoine Pouzet, et al.

    Primary mitochondrial diseases (PMDs) affect approximately 1 in 4300 individuals and cause early-onset neuromuscular and multisystem dysfunction with reduced lifespan. They result from pathogenic variants in mitochondrial or nuclear DNA that impair oxidative phosphorylation. Cytochrome c oxidase (COX; complex IV) deficiency is a well-established cause of PMD, leading to a broad spectrum of phenotypes. COXFA4 (cytochrome c oxidase subunit FA4), formerly NDUFA4, is a nuclear-encoded COX subunit, but its role in disease remains poorly defined. We report the largest genetically confirmed cohort of COXFA4-related PMD to date, comprising 13 individuals from 12 families with biallelic pathogenic COXFA4 variants. All present with Leigh-like encephalopathy and complete loss of COXFA4 protein; however, patient-derived fibroblasts retain residual COX activity, with upregulation of COXFA4L2 (cytochrome c oxidase subunit FA4-like 2), a poorly characterised paralog. Here, we show that COXFA4 is a late-stage COX assembly subunit and identify a paralog-mediated compensatory mechanism with translational potential.

  • Histologically atypical case of Gaucher disease type 1

    by Jessica Sabljak, Oliver Heath, Rebecca Halligan, Daryl R Cheng

    This report presents a case of childhood Gaucher disease type 1, a rare inherited metabolic disorder. Although the clinical symptoms were classical, the histological findings in this case were atypical and initially led to diagnostic uncertainty. The pathognomonic histological finding on bone marrow is Gaucher cells, which are lipid-engorged phagocytes secondary to the accumulation of glucosylceramide. These cells typically demonstrate diffuse and avid iron staining using a Prussian blue iron stain. In this case, although the histiocytes seen on bone marrow were abnormal, the absence of iron staining on bone marrow led to a large range of other diagnoses being considered. In retrospect, this anomaly was likely in the setting of prolonged iron deficiency and anaemia as a result of the insidious nature of this presentation. The prognosis of type 1 Gaucher disease is favourable, with current treatments significantly improving duration and quality of life. We explore the utility of a collaborative multidisciplinary approach in addressing diagnostic uncertainty and the importance in making a diagnosis for Gaucher disease type 1 in order to provide appropriate and targeted treatment.

  • Open Access

    Interstitial lung disease and pancreatic exocrine insufficiency in CADDS: Phenotypic expansion and literature review

    by Oliver Heath, Dinusha Pandithan, James Pitt, Elena Savva, Laura Raiti, Jenny Bracken, Moya Vandeleur, Martin B. Delatycki, Joy Yaplito‐Lee, Winita Hardikar, et al.

    Contiguous ABCD1/ DXS1357E deletion syndrome (CADDS) is a rare deletion syndrome involving two contiguous genes on Xq28, ABCD1 and BCAP31 (formerly known as DXS1357E). Only nine individuals with this diagnosis have been reported in the medical literature to date. Intragenic loss-of-function variants in BCAP31 cause the deafness, dystonia, and cerebral hypomyelination syndrome (DDCH). Isolated pathogenic intragenic variants in ABCD1 are associated with the most common peroxisomal disorder, X-linked adrenoleukodystrophy (X-ALD), a single transporter deficiency, which in its more severe cerebral form is characterised by childhood-onset neurodegeneration and high levels of very-long-chain fatty acids (VLCFA). While increased VLCFA levels also feature in CADDS, the few patients described to date all presented as neonates with a severe phenotype. Here we report a tenth individual with CADDS, a male infant with dysmorphic facial features who was diagnosed through ultra-rapid whole genome sequencing (WGS) in the setting of persistent cholestatic liver disease, sensorineural hearing loss, hypotonia and growth failure and developmental delay. Biochemical studies showed elevated VLCFA and mildly reduced plasmalogens. He died at 7 months having developed pancreatic exocrine deficiency and interstitial lung disease, two features we propose to be possible extensions to the CADDS phenotype. We also review the genetic, phenotypic, and biochemical features in previously reported individuals with CADDS.


  • Open Access

    Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre

    by Rebecca K. Halligan, R. Neil Dalton, Charles Turner, Katherine A. Lewis, Helen R. Mundy

    Background: Glycogen storage disease type Ib (GSD Ib) is a severe disorder of carbohydrate metabolism due to bi-allelic variants in SLC37A4. It is associated with neutropaenia and neutrophil dysfunction, which has recently been attributed to the accumulation of 1,5-anhydroglucitol-6-phosphate (1,5AG6P) within neutrophils. Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, is a novel therapy that reduces 1,5-anhydroglucitol (1,5AG) in plasma. Results: We report our experience in treating 8 paediatric GSD Ib patients with empagliflozin with a cumulative treatment time greater than 12 years. Treatment with a median dose of 5 mg (0.22 mg/kg height weight) of empagliflozin resulted in improvement in bowel health, growth, and laboratory parameters. Plasma 1,5AG levels reduced by a median of 78%. Baseline 1,5AG levels in our cohort were higher than in adult patients with GSD Ib. Hypoglycaemia on empagliflozin treatment occurred in 50% of our cohort. Conclusion: We report the largest single centre cohort of GSD Ib patients treated with empagliflozin to date. Treatment with SGLT2 inhibitors is a novel and favourable treatment option for neutropaenia and neutrophil dysfunction in GSD Ib. We suggest a low starting dose of empagliflozin with careful titration due to the risk of hypoglycaemia. The interpretation of 1,5AG levels and their role in treatment monitoring is yet to be established, and requires ongoing research.


  • Open Access

    Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre

    by Rebecca Halligan, Neil Dalton, Charles Turner, Katherine Lewis, Helen Mundy

    Background: Glycogen storage disease type Ib (GSD Ib) is a severe disorder of carbohydrate metabolism due to bi-allelic variants in SLC37A4. It is associated with neutropaenia and neutrophil dysfunction, which has recently been attributed to the accumulation of 1,5-anhydroglucitol-6-phosphate (1,5AG6P) within neutrophils. Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, is a novel therapy that reduces 1,5-anhydroglucitol (1,5AG) in plasma.Results: We report our experience in treating 8 paediatric GSD Ib patients with empagliflozin with a total treatment time greater than 12 years. Treatment with a median dose of 5mg (0.22mg/kg height weight) of empagliflozin resulted in improvement in bowel health, growth, and laboratory parameters. Plasma 1,5AG levels reduced by a median 78%. Baseline 1,5AG levels in our cohort were higher than in adult patients with GSD Ib. Hypoglycaemia on empagliflozin treatment occurred in 50% of our cohort.Conclusion: We report the largest single centre cohort of GSD Ib patients treated with empagliflozin to date. Treatment with SGLT2 inhibitors is a novel and favourable treatment option for neutropaenia and neutrophil dysfunction in GSD Ib. We suggest a low starting dose of empagliflozin with careful titration due to the risk of hypoglycaemia. The interpretation of 1,5AG levels and their role in treatment monitoring is yet to be established, and requires ongoing research.

  • Open Access

    The natural history of glycogen storage disease type Ib in England: A multisite survey

    by Rebecca Halligan, Fiona J. White, Bernd Schwahn, Karolina M. Stepien, Nazreen Kamarus Jaman, Mel McSweeney, Steve Kitchen, Joanna Gribben, Charlotte Dawson, Katherine Lewis, et al.

    Glycogen storage disease type Ib (GSDIb) is characterized by hepatomegaly and fasting hypoglycaemia as well as neutropaenia and recurrent infections. We conducted a retrospective observational study on a cohort of patients with GSDIb across England. A total of 35 patients, with a median age of 9.1 years (range 1‐39 years), were included in the study. We examined the genotype and phenotype of all patients and reported 14 novel alleles. The phenotype of GSDIb in England involves a short fasting tolerance that extends into adulthood and a high prevalence of gastrointestinal symptoms. Growth is difficult to manage and neutropaenia and recurrent infections persist throughout life. Liver transplantation was performed in nine patients, which normalized fasting tolerance but did not correct neutropaenia. This is the first natural history study on the cohort of GSDIb patients in England.


  • Wormian bones: thinking beyond osteogenesis imperfecta

    by Rebecca Kylie Halligan, Leanne Royle, Claire Lloyd, Roshni Vara, Moira Shang-Mei Cheung